Childhood Vaccinations

• Innate immune activation and antigen presentation: Upon vaccine administration, pattern recognition receptors (TLRs, NOD-like receptors) on dendritic cells and macrophages recognize pathogen-associated molecular patterns (PAMPs) in vaccines. For live vaccines, viral or bacterial antigens directly trigger innate immunity; for inactivated vaccines, adjuvants (aluminum salts, MF59, AS04) amplify pattern recognition receptor signaling. Antigen-presenting cells process vaccine antigens via the major histocompatibility complex (MHC) pathway—peptides are presented on MHC-I molecules (promoting CD8+ T cell responses) and MHC-II molecules (promoting CD4+ T cell responses). Activated dendritic cells migrate to draining lymph nodes where they present antigens to naive T cells, initiating the adaptive immune cascade.

• T cell-mediated immunity and cell-mediated response: Vaccine-activated dendritic cells provide three signals to naive CD4+ T cells: MHC-peptide complex binding (signal 1), co-stimulatory molecule engagement (B7-CD28; signal 2), and cytokine production (signal 3). These signals promote T cell proliferation and differentiation into Th1, Th2, or Th17 subsets depending on the vaccine type and cytokine milieu. Th1 cells produce interferon-gamma and promote intracellular pathogen immunity; Th2 cells produce IL-4, IL-5, and IL-13 to promote antibody responses; Th17 cells produce IL-17 for mucosal immunity and extracellular pathogen defense. Live vaccines typically generate robust Th1 responses and CD8+ cytotoxic T lymphocyte (CTL) responses due to direct viral or bacterial replication triggering MHC-I presentation. CD8+ CTLs are critical for controlling intracellular pathogens (measles, varicella) and provide durable immunity; they recognize and kill infected cells expressing vaccine-derived peptides on MHC-I.

• B cell activation, antibody production, and immunological memory: Activated CD4+ Th cells provide help to B cells through CD40-CD40L interaction and cytokine production, promoting B cell proliferation and differentiation into plasma cells and memory B cells. Plasma cells produce immunoglobulin M (IgM) initially, followed by class-switching to IgG (which provides durable systemic immunity and is the major opsonizing antibody), IgA (mucosal immunity at respiratory and gastrointestinal sites), and sometimes IgE (uncommon with vaccines). Somatic hypermutation in germinal centers generates high-affinity antibodies through B cell receptor selection. Memory B cells persist for years to decades and rapidly differentiate into plasma cells upon antigen re-exposure, providing rapid anamnestic (secondary) immune responses. The humoral immune response (B cell-mediated) is particularly important for vaccines against extracellular pathogens (diphtheria, tetanus, pertussis) and provides protection via opsonization, complement activation, and neutralization of toxins. Booster vaccinations at recommended intervals reactivate memory B and T cells, maintaining antibody titers and cellular immunity above protective thresholds.

• Live vaccine-induced immunity versus inactivated vaccine responses: Live attenuated vaccines (measles, mumps, rubella, varicella, rotavirus) undergo limited replication in vaccinated individuals, mimicking natural infection without causing disease in immunocompetent hosts. This replication elicits robust MHC-I presentation (strong CD8+ response), Th1 polarization, mucosal IgA production, and durable lifelong immunity often requiring only one or two doses. Inactivated vaccines (polio, hepatitis B, pertussis, influenza, pneumococcal) contain non-replicating antigens that primarily elicit Th2-biased B cell responses and antibody production but may generate weaker CD8+ CTL responses. Inactivated vaccines require multiple doses (priming series) to reach adequate antibody titers and may require periodic boosters to maintain immunity. The addition of adjuvants to inactivated vaccines enhances the magnitude and duration of immune responses by amplifying innate immune activation.

• Mucosal versus systemic immunity: Vaccines administered via mucosal routes (oral polio vaccine, rotavirus) induce both mucosal IgA responses (critical for preventing infection at mucosal surfaces) and systemic IgG responses. Systemic routes (intramuscular, subcutaneous) primarily generate systemic IgG responses. The mucosal immune system (gut-associated lymphoid tissue, nasopharyngeal-associated lymphoid tissue) operates semi-independently from systemic immunity and is crucial for pathogens with mucosal entry (rotavirus, poliovirus). Herd immunity is achieved when a sufficient proportion of the population is immune, reducing pathogen circulation such that even unvaccinated individuals are protected through reduced exposure—the threshold depends on the basic reproduction number (R₀) of each pathogen, ranging from ~85% (measles, R₀ ≈ 12-18) to lower percentages for diseases with lower R₀ values.

• Age-appropriate disease epidemiology and immunological considerations: Vaccines are timed to the age when children are most vulnerable to severe disease and when their immune systems can mount adequate responses. For example, measles vaccination is delayed until 12-15 months because maternal antibodies (transplacentally acquired IgG) interfere with vaccine efficacy in younger infants, but the risk of severe measles is highest in infants <6 months; therefore, infants aged 6-11 months may receive early MMR during outbreaks. Hepatitis B vaccination begins at birth because perinatal transmission from infected mothers poses high risk. Rotavirus vaccination must be completed by 8 months of age because intussusception risk is highest between 8-14 weeks and increases with vaccination age. The infant immune system, though capable of mounting responses to vaccines, requires multiple doses (priming) due to lower antibody production per dose and shorter antibody persistence compared to older children.

• Vaccine-preventable disease burden and mortality: Each vaccine in the childhood schedule targets a disease with significant historical or ongoing morbidity/mortality. Measles caused ~2.6 million deaths annually pre-vaccine (now <200,000 globally with vaccination). Polio caused paralysis in 1 of 200-500 infected children. Whooping cough (pertussis) killed ~200,000 children annually globally before vaccination. Haemophilus influenzae type b (Hib) caused meningitis, epiglottitis, and other invasive disease in ~20,000 U.S. children annually pre-vaccine. Pneumococcal disease causes bacteremia, meningitis, and pneumonia with case-fatality rates of 10-15% in children. These statistics justify universal vaccination programs.

• Immunization schedule modifications based on risk factors: Certain risk factors necessitate accelerated, delayed, or additional vaccination schedules. Asplenic patients (functional or anatomic asplenia) require meningococcal, pneumococcal, and Hib vaccination urgently due to high risk of overwhelming sepsis from encapsulated organisms. HIV-infected children on antiretroviral therapy with CD4 counts >200 cells/μL may receive most vaccines but should avoid live vaccines until CD4 >200 cells/μL for ≥3 months; timing and spacing of vaccines may be adjusted. Premature infants are vaccinated according to chronological age (not corrected age) from birth onwards, but some experts recommend age correction for children <2 years born <32 weeks gestation. Immunocompromised children (from chemotherapy, severe combined immunodeficiency, DiGeorge syndrome) require careful scheduling to avoid live vaccines during active immunosuppression. Chronic liver disease, diabetes, and chronic kidney disease are risk factors necessitating certain vaccines (hepatitis A/B, influenza, pneumococcal). Close contacts of immunocompromised persons should receive inactivated vaccines but avoid live vaccines that could transmit vaccine virus.

• Geographic and epidemiological risk factors: Children traveling internationally require additional vaccines based on destination. Yellow fever vaccination is required for travel to endemic areas in Africa and South America (not available in U.S. routine schedule but indicated for travelers). Japanese encephalitis, typhoid, and rabies post-exposure prophylaxis are travel-related considerations. Tuberculosis (BCG vaccine) is part of schedules in countries with high TB burden but not routinely used in the United States. Seasonal influenza vaccination is indicated annually for all children ≥6 months (especially those at high risk). Meningococcal serogroup B vaccination is now recommended for adolescents and young adults; some high-risk groups (complement deficiency, asplenia) require routine use.

• Medical conditions and medication exposure affecting vaccination: Thrombocytopenia (platelet count <50,000/μL) is a relative contraindication to intramuscular vaccines; subcutaneous administration is preferred. Egg allergy historically limited influenza and yellow fever vaccination, but most children with egg allergy tolerate these vaccines safely (with precautions). Latex allergy requires careful selection of vaccines packaged in non-latex vials. History of Guillain-Barré syndrome (GBS) within 6 weeks of a prior vaccine dose is generally considered a contraindication to that vaccine type due to potential recurrence, though the risk-benefit analysis may favor vaccination in high-risk populations. Recent immunoglobulin or blood product administration temporarily suppresses live vaccine responses; spacing of ≥3-11 months is recommended depending on the product type.

• Expected vaccine reactions and local effects: Pain, erythema, and induration at the injection site occur in 25-75% of vaccine recipients within 24-48 hours and typically resolve within 3-5 days without intervention. These reactions reflect normal inflammatory responses to intramuscular injection and are more common with acellular pertussis vaccine and inactivated polio vaccine. Sterile abscess formation at the injection site is rare but may occur with certain vaccines (particularly older pertussis vaccines and BCG) and resolves spontaneously over weeks to months. Lymphadenitis (inflammation of regional lymph nodes draining the injection site) occasionally occurs and is usually self-limited.

• Systemic vaccine reactions (mild to moderate): Fever is common after live vaccines (measles, rubella, varicella) occurring 5-12 days post-vaccination and lasting 1-2 days; fever in this temporal window after MMR or varicella vaccination is expected and usually benign, though it may trigger febrile seizures in genetically predisposed children. Irritability, drowsiness, or decreased appetite may accompany vaccination. Myalgias and malaise are typical of inactivated vaccines. Rash occurs in 5% of varicella vaccine recipients (typically 7-21 days post-vaccination) and is usually mild with <50 lesions; varicella-like rash may occur in unvaccinated contacts of vaccinated children (rare, indicating vaccine virus transmission). Urticaria or angioedema may indicate allergic reactions to vaccine components (gelatin, antibiotics, egg protein).

• Specific vaccine-strain manifestations: Measles vaccine virus occasionally causes rash and fever indistinguishable from natural measles but is generally milder. Mumps vaccine may cause parotitis and low-grade fever 1-3 weeks after vaccination. Rubella vaccine may cause arthralgias (20-40% of adult women, rare in children) or arthritis (3-10% of adult women) occurring 5-21 days post-vaccination. Rotavirus vaccine is typically well-tolerated with minimal systemic symptoms but carried a risk of intussusception with earlier formulations (withdrawn from market). Varicella vaccine causes mild vesicular rash in 3-5% of recipients. Oral polio vaccine (OPV) rarely causes vaccine-derived poliovirus (VDPV) in immunocompromised recipients; inactivated polio vaccine (IPV) eliminates this risk.

• Neurological symptoms and serious adverse events: Febrile seizures may follow vaccination, particularly after MMR, varicella, or whole-cell pertussis vaccines, due to fever-triggered seizures in susceptible children; these are typically brief, self-limited, and do not cause permanent neurological damage. Guillain-Barré syndrome (GBS) is a rare post-vaccination complication (incidence ~1-2 cases per million vaccine doses) characterized by ascending paralysis, sensory symptoms, and dysautonomia; temporal proximity to influenza or meningococcal vaccines has been epidemiologically associated, though absolute risk remains very low and benefits generally outweigh risks. Transverse myelitis and optic neuritis have been rarely reported temporally related to vaccines but causal relationship remains unclear. Acute disseminated encephalomyelitis (ADEM) is an extremely rare post-vaccination complication involving multifocal demyelination of brain and spinal cord.

• Hypersensitivity and anaphylaxis: Immediate anaphylaxis (urticaria, angioedema, bronchospasm, hypotension, laryngeal edema) typically occurs within minutes to 30 minutes of vaccination. Component-specific allergies include gelatin (present in some MMR, varicella, and influenza vaccines), neomycin (in several vaccines), and egg protein (in influenza and yellow fever vaccines). Latex allergy may be triggered by latex-containing vial stoppers. True IgE-mediated anaphylaxis to vaccines is rare (estimated 1-2 cases per million doses), and severe allergic reactions generally reflect hypersensitivity to specific vaccine components rather than the antigen itself.

• Timing considerations distinguishing vaccine-related from coincidental events: Temporal relationships are critical. Expected adverse events occur within specific windows (fever 5-12 days post-MMR, local reactions within 48 hours). Coincidental illnesses unrelated to vaccination occur randomly relative to vaccination. The Vaccine Adverse Event Reporting System (VAERS) captures all reported temporal associations but cannot establish causation; further epidemiological investigation distinguishes coincidental from causal relationships. Brighton Collaboration case definitions provide standardized criteria for diagnosing specific vaccine adverse events, aiding in causality assessment.

• Assessment of vaccination status and immunity: Documentation review of previous vaccination records (vaccination cards, medical records, state registries) is the first step; vaccination records should include vaccine name, date administered, route, site, lot number, and administrator name. Immunization information systems (IIS) or state registries centralize records and allow verification of completed vaccinations. For children with missing or incomplete records, consensus guidelines recommend considering doses valid if administered ≥4 weeks apart from preceding doses (for spacing-dependent vaccines) and at age-appropriate intervals, rather than restarting the series. Serological testing for immunity may be indicated when prior vaccination status is unknown or when documented evidence of

Immediate stabilisation (vaccine-related emergency)

• Anaphylaxis: epinephrine is first-line — 0.01 mg/kg IM of the 1 mg/mL concentration into the anterolateral thigh (maximum 0.3 mg in children), repeated every 5–15 minutes as needed. Adjuncts (H1 antihistamine, corticosteroid, inhaled beta-agonist) treat symptoms only and never substitute for epinephrine. CDC/ACIP requires every vaccinating site to stock epinephrine and to observe recipients for 15 minutes (30 minutes if prior allergic history) — this also captures vasovagal syncope, most common in adolescents, which is managed by supine positioning, not epinephrine.

First-line "therapy" — completing the series

• Adherence to the CDC/ACIP–AAP–AAFP harmonized immunization schedule: the therapeutic intervention itself. Doses given up to 4 days before the minimum interval are counted as valid (the 4-day grace period).
• Catch-up immunization: for incomplete records, ACIP directs use of the catch-up schedule with minimum intervals — never restart a series. Serology may substitute for revaccination in select circumstances but is not routinely needed.
• Symptomatic care: acetaminophen for post-vaccination fever or injection-site pain. Prophylactic antipyretics before vaccination are discouraged because they blunt antibody titers.

Escalation — post-exposure and high-risk situations (ACIP/AAP Red Book)

• Measles: MMR within 72 hours of exposure, or immune globulin within 6 days for infants, pregnant women, and immunocompromised contacts.
• Varicella: vaccine within 5 days of exposure; VariZIG instead for immunocompromised patients, pregnant women, and susceptible neonates.
• Hepatitis B: infant of an HBsAg-positive mother receives hepatitis B vaccine and HBIG at separate sites within 12 hours of birth.
• Tetanus-prone wounds: tetanus toxoid–containing vaccine ± tetanus immune globulin based on dose history.

Contraindicated

• Live vaccines (MMR, varicella, rotavirus, LAIV): severe immunodeficiency (SCID, active chemotherapy, high-dose steroids ≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥14 days), advanced HIV, and pregnancy.
• Anaphylaxis to a prior dose or component contraindicates that vaccine; encephalopathy within 7 days of a pertussis-containing dose contraindicates further pertussis component (use DT/Td).
• Rotavirus: contraindicated with SCID or prior intussusception.
• Not contraindications: mild illness, low-grade fever, current antibiotics, breastfeeding, prematurity, or family history of adverse events.

Emergencies

• Anaphylaxis: IgE-mediated degranulation against a vaccine excipient (gelatin, neomycin, yeast) rather than the immunizing antigen. Signalled by urticaria, stridor, wheeze, and hypotension within minutes. Immediate IM epinephrine; report to VAERS and refer for allergy evaluation.
• Intussusception after rotavirus vaccine: vaccine-induced lymphoid hyperplasia of Peyer patches creates a lead point. Signalled by paroxysmal crying with leg-drawing, currant-jelly stool, and a sausage-shaped right-sided mass; ultrasound shows the target sign. Air or contrast enema is both diagnostic and therapeutic; surgery if reduction fails or perforation is suspected.
• Disseminated live-vaccine infection in undiagnosed immunodeficiency: unchecked replication of attenuated virus or BCG in SCID or advanced HIV, presenting as progressive vaccine-strain varicella, giant-cell measles pneumonitis, or BCG-osis. This is why ACIP defers live vaccines when a sibling has a known immunodeficiency until the infant is evaluated.

Non-emergent but tested

• Febrile seizure: cytokine-driven fever peaking 5–12 days after MMR or varicella. Risk is higher with the combination MMRV than with separate MMR and varicella for the first dose at 12–47 months, so ACIP prefers separate injections for dose one unless the parent prefers fewer shots.
• Arthus reaction: type III immune-complex hypersensitivity in a hyperimmune host given tetanus/diphtheria toxoid too frequently; signalled by severe, painful whole-arm swelling 4–12 hours after injection. Defer further toxoid doses.
• Post-MMR thrombocytopenia: transient immune-mediated platelet destruction with petechiae 1–6 weeks after vaccination; typically self-limited.
• Guillain–Barré syndrome: molecular mimicry; rare, historically linked to influenza and meningococcal conjugate vaccines. Ascending weakness with areflexia; monitor vital capacity, as respiratory failure is an emergency.
• Shoulder injury related to vaccine administration (SIRVA): injection too high into the subdeltoid bursa producing persistent shoulder pain and limited range of motion — a technique complication, not an immune one.
• Complications of non-vaccination: measles pneumonia, encephalitis, and subacute sclerosing panencephalitis; Hib epiglottitis; overwhelming pneumococcal sepsis in asplenia.

• Anaphylaxis after any vaccine → epinephrine IM, not antihistamine: the single best next step in a stem describing hives plus wheeze or hypotension minutes after an injection. A teenager who faints immediately after a shot has vasovagal syncope — lay them flat; this is the classic distractor.
• Egg allergy is no longer a barrier to influenza vaccination: ACIP states any age-appropriate influenza vaccine may be given regardless of egg allergy severity, with no special observation period beyond the routine one. Anaphylaxis to a prior dose of the same vaccine remains a true contraindication.
• Never restart an interrupted series: the exam tests the "lapsed schedule" child — resume with the next dose using ACIP catch-up minimum intervals. Serologic testing to "prove" immunity is usually the wrong answer.
• Encephalopathy within 7 days of a pertussis-containing vaccine is the classic contraindication to further pertussis antigen — switch to DT/Td. Distinguish this from a simple febrile seizure or hypotonic-hyporesponsive episode, which are precautions, not absolute contraindications.
• Live vaccines and immunosuppression: MMR and varicella are contraindicated in severe immunosuppression, but HIV-infected children who are not severely immunosuppressed should receive them; MMRV combination is not recommended in HIV. High-dose steroids for ≥14 days require a waiting interval after discontinuation before live vaccines.
• Two live parenteral vaccines must be given the same day or ≥4 weeks apart; interferon from the first blunts take of the second. Inactivated vaccines have no such spacing rule.
• HBsAg-positive mother → hepatitis B vaccine plus HBIG within 12 hours at separate sites. If maternal status is unknown, give the vaccine at birth and test the mother.
• Asplenia, sickle cell disease, complement deficiency, or eculizumab therapy → meningococcal and pneumococcal vaccination; this is the association most often tested alongside overwhelming encapsulated-organism sepsis.
• Common distractors that are NOT contraindications: mild upper respiratory illness, low-grade fever, current antibiotic use, breastfeeding, prematurity (vaccinate by chronological age), and a household contact who is pregnant or immunocompromised (inactivated vaccines are fine; MMR and varicella are also acceptable in household contacts).